• Earlier in May, Savara Inc. reported new Phase 3 IMPALA-2 data at the ATS 2026 meeting showing that nebulized molgramostim improved exercise capacity and related measures in adults with autoimmune pulmonary alveolar proteinosis, while also posting a wider quarterly net loss of US$37.28 million.
• The convergence of clinically meaningful functional gains in a rare lung disease and preparations ahead of an FDA Priority Review has sharpened attention on molgramostim’s potential role in the aPAP treatment landscape.
• Next, we’ll examine how the new IMPALA-2 exercise and biomarker findings shape Savara’s investment narrative around molgramostim’s potential approval.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Savara's Investment Narrative?

For Savara, the big-picture thesis still lives or dies on molgramostim: a single, late-stage asset aiming to become the first treatment for autoimmune PAP across the U.S., Europe and the U.K. To own the stock, you need to be comfortable with zero revenue today, widening quarterly losses of about US$37.28 million, and a valuation that already prices in meaningful success. The most important near-term catalysts remain the November 22 FDA PDUFA date and parallel European and U.K. reviews. The new IMPALA-2 exercise and biomarker data slot directly into this story by reinforcing the overall clinical package ahead of those decisions, rather than changing it. That likely makes the update supportive but not transformational, while the core risk around regulatory outcomes and future commercial execution is unchanged.

However, there is one execution risk that current shareholders should not ignore. Our expertly prepared valuation report on Savara implies its share price may be too high.

Exploring Other Perspectives

The single Simply Wall St Community fair value estimate sits at US$10.81, leaving you with one clear reference point rather than a spread of opinions. Against that, the recent IMPALA-2 exercise data and ongoing FDA Priority Review keep the focus squarely on regulatory risk and whether Savara can convert promising clinical signals into a sustainable commercial business.

Explore another fair value estimate on Savara - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Savara research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Savara research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Savara's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.